

Purified anti-human FOXP3 Antibody

Catalog# / Size	320101 / 25 µg 320102 / 100 µg
Clone	206D
Regulatory Status	RUO
Other Names	Forkhead box protein P3, Scurfin, JM2, IPEX, Zinc finger protein JM2
Isotype	Mouse IgG1, κ
Description	FOXP3 is a 50-55 kD transcription factor, also known as Forkhead box protein P3, Scurfin, JM2, or IPEX. It is proposed to be a master regulatory gene and more specific marker of T regulatory cells than most cell surface markers (such as CD4 and CD25). Transduced expression of FOXP3 in CD4 ⁺ /CD25 ⁻ cells has been shown to induce GITR, CD103, and CTLA4 and impart a T regulatory cell phenotype. FOXP3 is mutated in X-linked autoimmunity-allergic dysregulation syndrome (XLAAD or IPEX) in humans and in "scurfy" mice. Overexpression of FOXP3 has been shown to lead to a hypoactive immune state suggesting that this transcriptional factor is a central regulator of T cell activity. In human, unlike in mouse, two isoforms of FOXP3 have been reported: one (FOXP3) corresponding to the canonical full-length sequence; the other (FOXP3 δ2) lacking exon 2. The 206D antibody recognizes human FOXP3 epitope in the region of amino acids 105-235.

Product Details

Verified Reactivity	Human
Reported Reactivity	Baboon, Cynomolgus, Rhesus, Pigtailed Macaque
Antibody Type	Monoclonal
Host Species	Mouse
Immunogen	Full-length FOXP3 protein
Formulation	This antibody is provided in phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography.
Concentration	0.5 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C.
Application	WB - Quality tested ICFC, IHC-F, IHC-P - Reported in the literature, not verified in house
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent intracellular staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.5 µg per 10 ⁶ cells in 100 µl volume. For Western blotting, the suggested working dilution(s) is ≤ 5.0 µg/ml in antibody dilution buffer. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes	Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections ¹ and formalin-fixed paraffin-embedded sections ^{1,8,19-20} , and Western blotting ¹ . The binding of 206D to FOXP3 can be partially blocked by 259D, but 206D does not show significant blocking effect on 259D binding. NOTE: For flow cytometric staining with this clone, True-Nuclear™ Transcription Factor Buffer Set (Cat. No. 424401) offers improved staining and is highly recommended.

Application References

(PubMed link indicates BioLegend citation)

1. Roncador G, *et al.* 2005. *Eur. J. Immunol.* 35:1681.(IHC)
2. Yang ZZ, *et al.* 2006. *Blood* 107:3639.
3. Liu W, *et al.* 2006. *J. Exp. Med.* 203:1701.[PubMed](#)
4. Bollyky PL, *et al.* 2007. *J. Immunol.* 179:744.
5. Bell MP, *et al.* 2007. *J. Immunol.* 179:1893.

6. Tran DQ, *et al.* 2007. *Blood* doi:10.1182/blood-2007-06-094656. [PubMed](#)
7. Gao Q, *et al.* 2007. *J Clin Oncol*.25:2586.(IHC) [PubMed](#)
8. Pillai V, *et al.* 2008. *Blood* 111:463. [PubMed](#)
9. Zheng Y, *et al.* 2008. *J. Immunol.* 181:1683. [PubMed](#)
10. Zonios DI, *et al.* 2008. *Blood* 112:287. [PubMed](#)
11. Kavanagh B, *et al.* 2008. *Blood.* [PubMed](#)
12. Nevala WK, *et al.* 2009. *Clin Cancer Res.* 15:1931. [PubMed](#)
13. Grant J, *et al.* 2009. *Cytometry B Clin Cytom.* 76:69. [PubMed](#)
14. Nigam P, *et al.* 2010. *J. Immunol.* 184:1690. [PubMed](#)
15. Kmiecik M, *et al.* 2009. *J. Transl. Med.* 7:89. (ICFC) [PubMed](#)
16. Hartigan-O'Connor DJ, *et al.* 2007. *J Exp Med.* 204:2679. [PubMed](#)
17. Raghaven S, *et al.* 2009. *Ann Rheum Dis.* 68:1908. [PubMed](#)
18. Hodi FS, *et al.* 2014. *Cancer Immunol Res.* 2:632.(IHC) [PubMed](#)
19. Szios E, *et al.* 2015. *Clin Cancer Res.* 21:2840.(IHC) [PubMed](#)

Product Citations

1. Chen S, *et al.* 2020. *Transl Lung Cancer Res.* 1.404861111. [PubMed](#)
2. Kavanagh B, *et al.* 2008. *Blood.* 112:1175. [PubMed](#)
3. Chen P, *et al.* 2021. *J Immunother Cancer.* 9: [PubMed](#)
4. Haymaker C, *et al.* 2021. *Cancer Discov.* 11:1996. [PubMed](#)
5. Richardson LG, *et al.* 2020. *Oncoimmunology.* 9:1806662. [PubMed](#)
6. Riquelme E *et al.* 2019. *Cell.* 178(4):795-806. [PubMed](#)
7. Parra E, *et al.* 2017. *Sci Rep.* 10.1038/s41598-017-13942-8. [PubMed](#)
8. Nugent JL, *et al.* 2021. *iScience.* 24:103421. [PubMed](#)
9. Karandikar V 2008. *Blood.* 111:463. [PubMed](#)
10. Werneburg S, *et al.* 2020. *Immunity.* 52(1):167-182.e7. [PubMed](#)
11. Lin JR *et al.* 2018. *eLife.* 7 pii: e31657. [PubMed](#)
12. Mitra A, *et al.* 2020. *Nat Commun.* 11:1839. [PubMed](#)
13. Liu X, *et al.* 2022. *STAR Protoc.* 3:101310. [PubMed](#)
14. Burlingame EA, *et al.* 2021. *Cell Rep Methods.* 1: [PubMed](#)
15. Boucher Y, *et al.* 2021. *NPJ Precis Oncol.* 5:62. [PubMed](#)
16. Derks S, *et al.* 2020. *Ann Oncol.* 31:1011. [PubMed](#)
17. Li Y, *et al.* 2019. *Front Immunol.* 0.460416667. [PubMed](#)
18. Vence L, *et al.* 2019. *Clin Cancer Res.* 25:6501. [PubMed](#)
19. de Groot J, *et al.* 2020. *Neuro Oncol.* 539:22. [PubMed](#)
20. Helmink BA, *et al.* 2020. *Nature.* 577:549. [PubMed](#)
21. Li W, *et al.* 2018. *BMC Cancer.* 1.589583333. [PubMed](#)
22. Xie S, *et al.* 2020. *Ann Transl Med.* 1.384027778. [PubMed](#)
23. Zeigler-Johnson C, *et al.* 2016. *PLoS One.* 11: 0159109. [PubMed](#)
24. Gao Q, *et al.* 2007. *J Clinical Oncology.* 25:2586. [PubMed](#)
25. Donnelly C, *et al.* 2018. *Sci Rep.* 0.625. [PubMed](#)
26. Msaouel P, *et al.* 2020. *Cancer Cell.* 720:37. [PubMed](#)
27. Wang H, *et al.* 2021. *Onco Targets Ther.* 14:2953. [PubMed](#)
28. Hodi F, *et al.* 2014. *Cancer Immunol Res.* 2:632. [PubMed](#)
29. Zsiros E, *et al.* 2015. *Clin Cancer Res.* 21:2840. [PubMed](#)
30. Sadigh S, *et al.* 2020. *Am J Clin Pathol.* 387:153. [PubMed](#)
31. Durgin JS, *et al.* 2021. *Front Oncol.* 11:669071. [PubMed](#)
32. Jiang M, *et al.* 2021. *J Immunother Cancer.* 9: [PubMed](#)
33. Luoma AM, *et al.* 2020. *Cell.* 182(3):655-671.e22. [PubMed](#)
34. Amaria RN, *et al.* 2018. *Nat Med.* 24:1649. [PubMed](#)
35. Blessin NC, *et al.* 2019. *Dis Markers.* 2019:5160565. [PubMed](#)
36. Zonios D, *et al.* 2008. *Blood.* 112:287. [PubMed](#)

RRID

AB_430880 (BioLegend Cat. No. 320101)
 AB_430881 (BioLegend Cat. No. 320102)

Antigen Details

Structure	Forkhead/winged-helix transcription factor family, approximately 50 kD, contains zinc finger and forkhead domains
Distribution	Nuclear; expressed in T regulatory cells
Function	Transcription factor proposed to be a master regulatory gene in T regulatory cell development and a critical factor for immune homeostasis
Interaction	Interacts with DNA
Cell Type	Tregs
Biology Area	Cell Biology, Immunology, Transcription Factors
Molecular Family	Nuclear Markers
Antigen References	<ol style="list-style-type: none"> 1. Hori S, <i>et al.</i> 2003. <i>Science</i> 299:1057. 2. Gandhi R, <i>et al.</i> 2010. <i>Nat. Immunol.</i> 11:846.

Regulation FOXP3 is present at high levels in T regulatory cells, it can also be induced by T cell activation.

Gene ID [50943](#)

Related Protocols

[True-Nuclear™ Transcription Factor Staining Protocol for 96-Well U Bottom Plate](#)


[True-Nuclear™ Transcription Factor Staining Protocol for 5mL Tubes](#)

[Western Blotting Protocol](#)

Other Formats

Purified anti-human FOXP3, Alexa Fluor® 488 anti-human FOXP3, Alexa Fluor® 647 anti-human FOXP3, FITC anti-human FOXP3, Pacific Blue™ anti-human FOXP3, PE anti-human FOXP3, PE/Dazzle™ 594 anti-human FOXP3, True-Nuclear™ One Step Staining Human Treg Flow™ Kit (FOXP3 Alexa Fluor® 488/CD25 PE/CD4 PerCP), Brilliant Violet 421™ anti-human FOXP3, KIRAVIA Blue 520™ anti-human FOXP3, Spark NIR™ 685 anti-human FOXP3 Antibody

Product Data



Cell extract from HEK293T cells transfected with human FoxP3 cDNA was resolved by electrophoresis, transferred to nitrocellulose, and probed with monoclonal anti-FoxP3 antibody (clone 206D). Proteins were visualized using a goat anti-mouse secondary conjugated to HRP and a chemiluminescence detection system.

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587